Please assess the completion status of the following clinical trial:

Trial Title: BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed advanced pancreatic adenocarcinoma~  * Distant metastases OR~ * Locoregional disease that has failed or is not amenable to locoregional therapy~* No de novo locoregional disease~* No known brain metastases~PATIENT CHARACTERISTICS:~Age:~* Adult~Performance status:~* Zubrod 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* SGOT or SGPT no greater than 2.5 times ULN~* Alkaline phosphatase less than 2.5 times ULN~Renal:~* Creatinine no greater than 1.5 mg/dL~Cardiovascular:~* No recent myocardial infarction, unstable angina, or life-threatening arrhythmia~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer in remission~* No prior severe hypersensitivity reaction to drugs containing Cremophor EL~* No active or uncontrolled infection~* No severe psychiatric disorders~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior neoadjuvant, adjuvant, or primary immunotherapy for advanced pancreatic cancer~* No concurrent anticancer immunotherapy~Chemotherapy:~* No prior neoadjuvant, adjuvant, or primary chemotherapy for advanced pancreatic cancer~* No other concurrent anticancer chemotherapy~Endocrine therapy:~* No prior neoadjuvant, adjuvant, or primary hormonal therapy for advanced pancreatic cancer~* No concurrent anticancer hormonal therapy~Radiotherapy:~* No prior neoadjuvant, adjuvant, or primary radiotherapy or chemoradiotherapy for advanced pancreatic cancer~* Prior palliative radiotherapy allowed if at least 1 lesion remains outside of radiation field or at least 1 lesion has progressed since radiotherapy~* No concurrent anticancer radiotherapy except palliative radiotherapy to non-target metastatic sites~Surgery:~* At least 2 weeks since prior surgery for pancreatic cancer and recovered~Other:~* No other concurrent anticancer therapy~* No concurrent herbal or unconventional therapy (e.g., St. John's Wort)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).